The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMediumUpdated•Originally published 1 May 2026•Updated 2 May 2026•

1 min read

Revolution Medicines Stock Jumps 7.2% on Positive Pancreatic Cancer Drug Results

Key Facts

1The U.S. FDA authorized early access to Revolution Medicines' pill for previously treated pancreatic cancer patients prior to formal regulatory approval.

Revolution Medicines (RVMD) shares surged 7.2% following the release of positive clinical trial results for its pancreatic cancer drug, daraxonrasib. The trial demonstrated a statistically significant improvement in overall survival rates compared to standard chemotherapy, marking a major milestone for the treatment. This clinical success follows the FDA's recent decision to grant expanded access to the drug for patients with limited options. Full Phase 3 data is scheduled for presentation at the 2026 ASCO Annual Meeting, providing a clear timeline for further regulatory progress. The results significantly bolster the company's position in the biotech sector and validate the therapeutic potential of its oncology pipeline. Investors are viewing these developments as a strong bullish signal for the firm's long-term commercial prospects.

about 1 month ago

Version History

Version 1about 1 month ago

What changed: The story was updated to include a 7.2% stock price increase and clinical trial results showing the drug outperformed chemotherapy, along with the 2026 ASCO presentation timeline.